Health
Scientific Committees
Scientific Steering Committee (former MDSC)
Outcome of discussions
Updated
Report and
Scientific Opinion on the safety of hydrolysed proteins
produced from bovine hides. Initially adopted by the
Scientific Steering Committee at its meeting of 22-23 October
1998 and updated at its meeting of 25-26 May 2000
Executive Summary
The SSC was asked to prepare a
scientific opinion on the following question:
"Can hydrolysed protein (peptides and amino acids),
derived from bovine hides, be considered to be free of BSE
infectivity, independent from the source of the raw
material? If not, under which conditions of sourcing of the
material (geographical and animal) and/or of type of
material used (e.g. specified risk materials) and/or age of
animal and/or production process can it be considered as
safe?"
Opinion of the SSC:
The SSC is of the opinion that
hydrolysed proteins can be considered to be safe as long as
the raw material ("fleshing") entering the hydrolisation
process does not, for example through contamination, carry
a high infective load and an appropriate transformation
process is applied. Therefore, in order to prevent the risk
of propagation of BSE, no material from animals suspected
or known to carry the BSE agent, should be processed and
the raw material should only be obtained from healthy
animals. The following conditions should be fulfilled for
arriving at a safe product:
(a) If the material comes from a source
that is classified as BSE free or at negligible risk, the
production process should result in a safe products with
respect to all infectious agents other than TSE, but no
additional conditions related to BSE are
necessary.
(b) If the raw material comes from a
source with a lower BSE risk, the hides have to be carefully
prepared (brining, liming and intensive washing) and a
transformation process must be applied. This must include a
heat treatment with a proven capacity to reduce
BSE-infectivity. The heat/pressure/time conditions currently
used by the industry and which have been brought to the
attention of the SSC (
³
140°C/
³
3.6bar/
³
30minutes), and on which this opinion is
based, are regarded to be sufficient. These conditions are
considered to have a significant reduction potential: they
are more severe than those which have shown a reduction
potential of 10
3 (drying excluded) in the case of
rendering
1
. Moreover, the heat treatment is preceded
by a careful preparation. An additional alkaline treatment
(pH
³
11,
³
3h at T
³
80°C) would enhance the safety.
(c) The product should not be fed to
ruminants nor be used as fertiliser when the hides are
sourced from high risk countries, unless the following
production conditions are met. Measures must be in place to
minimise contamination of the hides with CNS tissue and the
hides have to undergo careful preparation (brining, liming
and intensive washing). A transformation process has to be
applied which includes a heat treatment and an alkaline
treatment. These treatments must have a capacity to reduce
BSE-infectivity. The heat/pressure/time conditions currently
used by the industry and which have been brought to the
attention of the SSC (heat treatment:
³
140°C/
³
3.6bar/
³
30minutes and an alkaline treatment at:
pH
³
11,
³
3h at T
³
80°C) are regarded to be
sufficient.
(d) Processes applying less severe
conditions would require a separate evaluation and could
probably not be regarded to be similarly safe.
Full Opinion of the SSC
The SSC was asked to prepare a
scientific opinion on the following question:
"Can hydrolysed protein (peptides and amino acids),
derived from bovine hides, be considered to be free of
BSE infectivity, independent from the source of the raw
material? If not, under which conditions of sourcing of
the material (geographical and animal) and/or of type of
material used (e.g. specified risk materials) and/or age
of animal and/or production process can it be considered
as safe?"
Opinion of the SSC:
The SSC is of the opinion that
hydrolysed proteins can be considered to be safe as long as
the raw material ("fleshing") entering the hydrolisation
process does not, for example through contamination, carry
a high infective load and an appropriate transformation
process is applied. Therefore, in order to prevent the risk
of propagation of BSE, no material from animals suspected
or known to carry the BSE agent, should be processed and
the raw material should only be obtained from healthy
animals
2
. The following conditions should be
fulfilled for arriving at a safe product:
(a) If the material comes from a source
that is classified as BSE free or at negligible risk, the
production process should result in a safe products with
respect to all infectious agents other than TSE, but no
additional conditions related to BSE are
necessary.
(b) If the raw material comes from a
source with a lower BSE risk, the hides have to be carefully
prepared (brining, liming and intensive washing) and a
transformation process must be applied. This must include a
heat treatment with a proven capacity to reduce
BSE-infectivity. The heat/pressure/time conditions currently
used by the industry and which have been brought to the
attention of the SSC (
³
140°C/
³
3.6bar/
³
30minutes), and on which this opinion is
based, are regarded to be sufficient. These conditions are
considered to have a significant reduction potential: they
are more severe than those which have shown a reduction
potential of 10
3 (drying excluded) in the case of
rendering
3
. Moreover, the heat treatment is preceded
by a careful preparation. An additional alkaline treatment
(pH
³
11,
³
3h at T
³
80°C) would enhance the safety.
(c) The product should not be fed to
ruminants nor be used as fertiliser when the hides are
sourced from high risk countries, unless the following
production conditions are met. Measures must be in place to
minimise contamination of the hides with CNS tissue and the
hides have to undergo careful preparation (brining, liming
and intensive washing). A transformation process has to be
applied which includes a heat treatment and an alkaline
treatment. These treatments must have a capacity to reduce
BSE-infectivity. The heat/pressure/time conditions currently
used by the industry and which have been brought to the
attention of the SSC (heat treatment:
³
140°C/
³
3.6bar/
³
30minutes
and an alkaline treatment at: pH
³
11,
³
3h at T
³
80°C) are regarded to be
sufficient.
However, if hides are coming from
animals certified as BSE-free which are processed on
dedicated lines, the conditions for lower risk countries
apply.
(d) Processes applying less severe
conditions would require a separate evaluation and could
probably not be regarded to be similarly safe.
The SSC considers that, as a general
principle which it applied also when considering the issues
of the safety of other products such as gelatine,
meat-and-bone meal, tallow and dicalcium phosphate, an
experimental verification of the capacity of the overall
process to reduce or eliminate BSE infectivity is needed.
The SSC is aware that presently a validation study on the
safety of hydrolysed proteins with respect to BSE
infectivity is ongoing. The above opinion may be amended
according to the results of this study.
Summary table: the safety of hydrolysed proteins
derived from hides from bovines and intended as animal
feed or fertiliser
Source
(classification as to
SSC)
|
Minimum conditions
|
BSE FREE or
NEGLIGIBLE RISK
|
-
Raw material to be obtained from
healthy animals.
-
The production process should
result in a safe products with respect to all
infectious agents other than TSE, but no
additional conditions related to BSE are
necessary.
|
LOWER RISK
|
-
Raw material to be obtained from
healthy animals.
-
An appropriate production process,
including (as brought to the attention of the SSC)
careful pre-treatment (including brining, liming and
intensive washing) and at least one heat treatment
at
³
140°C for
³
30 min
³
3.6bar
4
-
Regarding the molecular weight of the end
product: see section "Other considerations"
|
HIGH RISK
(If hides are coming from animals
certified as BSE-free, e.g. from certified
animals
5
or certified herds or closed
herds
6
, the conditions for lower risk
apply.)
|
No application as a ruminant feed
nor as a fertiliser, unless:
-
Raw material to be obtained from
healthy animals.
-
Measures in place to minimise
contamination of hides.
-
Appropriate production process,
including (as brought forward to the SSC): a careful
pre-treatment (including brining, liming and
intensive washing), a heat treatment (
³
140°C/
³
3.6bar/
³
30minutes)
12 and an alkaline treatment (pH
³
11,
³
3h at T
³
80°C)
12.
-
Regarding the molecular weight of the end
product: see section "Other considerations"
|
Status unknown
|
Consider as high risk until
otherwise proven.
|
Note: This Classification of
geographical risk does not prejudge the opinion of the SSC
on the TSE/BSE status of any country nor the OIE
classification.
Main elements of the scientific justification of the
answer
The infective load of a hide of an
infected bovine animal is estimated to be low because hides
itself have not been found to be infective and the main
source of infectivity could be contamination in the
slaughterhouse. It can be assumed that this load is further
reduced by the preparatory treatment in the tannery
(brining, liming and intensive washing). Accordingly it is
regarded to be unlikely that the fleshing entering into the
hydrolisation process carries a high infective load.
The industrial production processes which
have been brought to the attention of the SSC include at
least two steps, for which it can be assumed that they have a
capacity to reduce the infective titre of the input material.
A heat treatment at T
³
140°C for at least 30 min at a pressure of
3.6 bar is more severe than the heat treatment applied in
rendering (133°C/20'/3 bars) and it can hence be assumed that
at least the same infectivity reduction could be realised.
This assumption is further supported by the fact that the
material heated here is in a fluid phase and hence much
better penetrable than the particles entering a rendering
process. An alkaline treatment at pH
³
11 where the material is kept for 3h at
T
³
80°C is potentially similarly effective as
the alkaline treatment in the gelatine process which operates
at much lower temperatures but for much longer time. Even if
it is not known if the two processes are fully additive, the
hydrolisation process seems to have the capacity to reduce an
infective titre significantly.
Other considerations:
Given the complexity of the production
process the Scientific Steering Committee strongly recommends
that manufacturers implement and respect HACCP
7
procedures. It is essential to identify
and describe hazards and critical points for the production
process. Two of these points are the traceability and the
treatment at origin of the raw material (e.g. minimising the
contamination with specified risk materials, in particular
CNS-tissues), and the preparatory treatment of the hides
before fleshing (brining, liming, washing. No recycling of
treatment waters). It can also be assumed that the heat
treatments (T>=140°C, >=3.6bar, >=30min) and the
alkaline treatments are critical stages of the transformation
process and should be carefully respected and controlled.
Controlling the molecular weight would provide a good
verification of the appropriateness of an applied
transformation process. A value of a maximum molecular weight
of the hydrolysed proteins below 10.000 Daltons could be used
as an indicator
Having regard to considerations provided by the
TSE/BSE ad-hoc group at its meeting of 11 May 2000 and
which are detailed in the annexes 1, 2 and 3, it may be
concluded that a molecular weight of <10.000D cannot
be seen as an absolute guarantee for safety, per se. The
criterion is indicative, and not exclusive for the
quality of the hydrolysing process and of the safety
regarding possible residual TSE infectivity of the final
product. It seems theoretically possible that the
infectious fraction (segment, part) of the BSE-agent
could be smaller. However, a product with most of the
molecules having a MW of < 10.000D has most likely
been produced by means of production processes which,
together with appropriate sourcing and respecting the
other safety conditions given in the above cited
SSC-opinion, guarantee a safe product. A limited range of
molecular weights above the target value of less than
10.000D is therefore unlikely to affect the safety of the
final product, provided, of course, all the other
criteria of the opinion are complied with. Thus, a
molecular weight below 10.000D may be used as an
indicator but not as a safety guarantee per se.
Note: The above opinion of the SSC is based on the
report of the working group of the TSE/BSE ad hoc Group,
which was accepted by the TSE/BSE ad-hoc group and then by
the SSC, following critical discussion and review.
Report from the working group
1. Terms of Reference
The SSC was asked to deliver a
scientific opinion on the following question:
"Can hydrolysed protein (peptides and amino acids),
derived from bovine hides, be considered to be free of
BSE infectivity, independent of the source of the raw
material?
If not, under which conditions of sourcing of the
material (geographical and animal) and/or of type of
material used (e.g. specified risk materials) and/or age
of animal and/or production process can it be considered
as safe?"
2. Context
2.1 Legislative/policy/scientific aspects
Commission Decision 94/381/EC
8
concerning certain protection measures
with regard to BSE and the feeding of mammalian derived
protein, prohibits the feeding of proteins derived from
mammalian tissues to ruminant species.
The above Decision was amended by
Commission Decision 95/60/EC
9
to exempt some animal products and
by-products from the ban given that they present no health
risk.
Among these products, there are amino
acids obtained from hides by a process which involves
exposure of the material to a pH of 1 to 2 followed by a pH
of >11 followed by a heat treatment at 140°C for 30
minutes at 3.6 bar.
In Decision 95/60, the above derogation is
limited to amino acids and it is not extended to peptides as
well. In fact, the advice of the Scientific Veterinary
Committee
10
to the Commission on this issue
recommended only amino acids to be excluded from the feed
ban. This advice was used as scientific background for the
adoption of Decision 95/60.
2.2 References to previous opinions of the Committee
or other Commission Scientific Committees/international
bodies.
The SSC is not aware of any scientific
opinion on the safety of hydrolysed proteins from bovine
hides except the opinion of the Scientific Veterinary
Committee of 12.12.1994 on different proteins derived from
bovines, including amino acids (but not peptides). However,
given the similarities of the gelatine production process
when based on hides, reference is made to the different
opinions issued on this subject by various Scientific
Committees of the European Commission, the OIE, the WHO and
of the US-FDA
11
.
2.3 Definition of terms.
1. For the purpose of this opinion,
hydrolysed proteins (HPRO) are defined as mixtures
of polypeptides, peptides and amino acids obtained from the
hydrolysis of collagen contained in the fleshing derived
from bovine hides. Their production process includes
successive treatments: degreasing, acid treatment
12
, alkaline treatment (liming),
concentration, sterilisation, and filtration. Hydrolysed
proteins are used as feed for monogastric and ruminant
animals and as fertilisers, mainly for horticulture. It is
not used in pharmaceutical preparations or in foods.
2. Collagen is a family of fibrous proteins, with a
high tensile strength which are found in connective tissues
such as the organic matrices of hides, bones, tendons,
cartilage, cornea of the eye, blood vessels and teeth. The
structural unit of collagen is tropocollagen. This protein
is formed of three helical units wrapped around one another
with a right twist. Each of these helices contains about
1,000 amino acids. The amino acid sequence of collagen is
highly distinctive with every third residue as glycine
(35%). Other important amino acids are alanine (11%), and
proline (12%). The unusual hydroxyproline also occurs (9%)
and there are a few % of hydroxylysine.
3. Healthy animals are defined as animals which have
undergone an ante mortem inspection by an official
veterinarian where it was determined that the animals were
not suffering from a disease which is communicable to man
and animals and that they do not show symptoms or are in a
general condition such as to indicate that such disease may
occur and they show no symptoms of disease or of a disorder
of their general conditions which is likely to make their
meat unfit for human consumption. (Definition as given in
Directive 64/433/EEC, laying down the rules for ante mortem
inspection)
3. Assessment
3.1 Strategy adopted for the evaluation and risk
assessment
As for Gelatine the safety of hydrolysed
proteins depends
(a) on the risk, that the raw material
entering the production process carries the BSE agent,
and
(b) on the ability of the production
process to reduce or eliminate any residual infectivity,
and
(c) on the final use of the product (as
feed or fertiliser).
The assessment will discuss these three
risk-components separately before a final conclusion is
drawn.
3.2 Assessment of the risk, that the raw material
entering the production process for Hydrolysed Proteins
(HPORs) carries the BSE agent.
The typical hydrolysed proteins
manufacturing process uses "fleshing" (which may contain
residues from hides) as raw material (ASSALZOO, 28 May
1998).
The "fleshing" is made up of collagen,
elastic fibres, fat and muscular traces. As a by-product from
tanning, it is derived from hides which have been brined for
2 or more days, treated with sodium sulphide and lime at
pH
³
11 for at least 24 hours (liming process).
The hides are then washed with regular shaking. After
washing, the "subcutaneous layer" is mechanically separated
to obtain the "fleshing". Small parts of the hides may remain
in the fleshing.
The hazard
The hazard is here defined as the event
that the raw material for the hydrolysis process carries
the BSE infective agent. It depends on the event that the
hides, the basic raw material, are carrying infectivity and
the efficiency of the tanning process, precursor to the
hydrolysis, to reduce that infectivity.
Infectivity of hides
The infectivity of hides with regard to
BSE has been assessed by the SSC in its opinion on SRM of
9/12/97. In line with other scientific committees and
international bodies (WHO
13
) the SSC confirmed that no infectivity
was detected in connective tissue and hides. This material
has therefore not been classified as specified risk
material.
However, the SSC underlined in the same
opinion its view that contamination of non-infective
tissues with highly infective tissues (e.g. brain, spinal
cord) could pose a risk, particular if hide from the head
is used. Also in its opinion on the safety of Gelatine
(March, 1998) the SSC concluded that hides are safe, as
long as contamination can be avoided.
The Scientific Steering Committee has also
stated
14
that in cattle, sheep and goats TSE
infectivity is not limited to nervous (brain) proteins but is
also present in the lympho-reticular system of sheep. So far
this has not been found for BSE infected bovines, even after
spleen and lymph nodes were injected intercerebrally into
cattle. The same holds true for infectivity in peripheral
nerves, which has been shown for SCRAPIE in sheep but never
for BSE in cattle.
Contamination
Contamination of hides with CNS (Central
Nervous System) may result (a) from brain tissue spilt over
the outside of the hides when stunning or pithing the
animal, and (b) from spinal cord tissue spilt over the
outside of the hide when removing the head. No data
are available on the amount of CNS material that can be
attached to a hide by this way.
Reduction of the infectivity of hides by the tanning
process:
Manzke et al., 1996, have shown that
during the degreasing step in the gelatine process (largely
washing of crushed bones with hot water), 98-99% of the
protein of nervous origin (e.g. S100, GFAP and others) are
removed. The detection method used (ELISA test) was very
sensitive with a detection threshold from 30 pg for S100
and 7 pg for GFAP.
Hides are not only washed but first
brined for 2 or more days, then depilated and subsequently
exposed to an alkaline treatment. Only then the hides are
washed with hot water in order to clean them from the
brining residues. This series of processes is likely to
reduce any contamination beyond the level that can be
reached by washing alone.
However, the SSC notes
15
that the above conclusion may be valid for
the reduction in protein levels, but not necessarily for the
reduction of BSE infectivity to the same extend. Prions, or
any other yet unidentified BSE-agent, are not necessarily
removed in the same way as nervous proteins.
Infective load of fleshing resulting from a hide of a
BSE-infected cattle
If hides from BSE-infective cattle are
processed in a tannery, a part of the initial infectivity
will be eliminated/washed away, but another part may
survive that treatment. The resulting infective load of a
single hide, which has been contaminated by infected CNS
tissue, is depending on the total amount of CNS spilt on
the hides and the capacity of the tanning process to reduce
this load. Possible mechanisms for such a reduction are
either of a physical or a chemical nature. The physical
impact is quite severe (depilation and washing) and could
be supported by the chemical impact of the liming. As a
result is it likely that the infective load of an
originally contaminated hide is significantly lower at the
end of the tanning process than before.
The SSC is of the opinion that it is unlikely that the
fleshing obtained from bovine hides contains high loads
of infectivity
.
BSE infectivity of the raw material which enters the
hydrolysis process.
The production of hydrolysed proteins
starts with the so-called fleshing, the subcutaneous layer
of bovine hides. This fleshing is processed in batches of 6
to 280 tons, equivalent to at least 350 hides per batch. As
the fleshing is more or less liquid (amorphous), it can be
assumed that any infectivity entering the batch is evenly
distributed in the batch, i.e. a good dilution can be
expected.
The probability that a batch contains
BSE infective is proportional to the risk that infected
animals are slaughtered and their hides are contaminated
with CNS from the infective animals. This risk is known as
the 'geographical risk' or the 'sourcing risk' because it
depends on the origin of the animal.
The infective titre of the fleshing
entering the hydrolysis process is depending on the
geographical risk: If a higher proportion of hides is
contaminated with BSE, the input titre increases
. The theoretically possible infective load of the
raw material entering the hydrolysis process is therefore
proportional to the geographical risk of the raw material
source.
Given the fact that the infective load
of the fleshing from an infected animal is not likely to be
high, the maximum infective load of the batch of the
fleshing entering the hydrolysis process is equivalent to
the level of one contaminated hide. It would only be
reached if all hides entering a batch would come from
infective cattle or would be contaminated with CNS from
infective cattle, a rather unlikely assumption.
Given the fact that hides are regarded to be free of
BSE infectivity, even if the animal is infected; given
the fact that the maximum infective load of a
contaminated hide is not likely to be high; given the
fact that it is unlikely that a high proportion of the
hides used for a batch of fleshing which enters the
hydrolysis process, could be contaminated;
the SSC is assuming that the infective load of the
batch of fleshing entering the hydrolysis process is
unlikely to be significant in countries which do not have
a high incidence of BSE.
Note on geographical risk
assessment:
The SSC has issued an opinion on
the information needed to assess the
epidemiological status of a country or region with
regard to TSE (23/01/98 and 20/2/98). In its
opinions on the safety of Gelatine, Tallow and MBM
(March, 1998), it has used three preliminary risk
categories for categorising the geographical origin
of animals: BSE free or of negligible risk; lower
BSE-risk; and higher BSE-risk. It is currently
preparing a methodology for assessing the
geographical risk on the basis of the information
requested.
The OIE, at its 66th Annual
General Session (29 May 1998), has discussed a new
version of the OIE International Animal Health Code
on Bovine Spongiform Encephalopathy (BSE). It
identifies four categories or zones with regard to
BSE:
1. BSE- free country or zone
(conditions defined).
2. Country (or zone) that has
not demonstrated a BSE free status and has not
declared any indigenous cases of the disease
(definition under study)
3. Country or zone with a low
incidence of BSE (definition under study)
4. Country or zone with a high
incidence of BSE (definition under study).
For consistency reason this
opinion will use the same classification as the
previous opinions on gelatine, tallow and MBM. It
is, however, evident that this classification may
have to be revised, once a final classification
scheme is defined. This may make a revision of the
opinions on gelatine, tallow, MBM and other
bovine-derived products necessary.
|
3.3 Assessment of the ability of the
production process to reduce or eliminate any residual
infectivity.
The second element, which is essential
for the safety of the final product, is the ability of the
hydrolysis process to reduce or eliminate the
BSE-agent.
3.31 Description of the typical manufacturing
process
Two main schemes have been found to be
applied by industry but deviations are possible. They are
distinguished by a different sequence. Scheme (I) includes
two separate filtration and two heating steps while scheme
(II) has only one filtration and one heat treatment but
adds a deodorification to the process.
Scheme I.
I-1.
Homogenisation: The raw material is heated, ground
and homogenised.
I-2.
Acid hydrolysis
16
: By heating to 80-100°C and mixing with
sulphuric acid (H
2SO
4). This phase lasts 6 hours. The pH is between
0 and 2.
I-3. Degreasing in acid phase: At the end of the
acid hydrolysis phase, the fat is separated and processed
in a stripping plant, finally stored and utilised for
industrial applications.
I-4.
Alkaline treatment: The proteinic degreased phase is
mixed with lime (Ca(OH)
2) in order to have a pH above 11. It is heated
for 2 h to 80-90°C and for 1h to 90-100°C.
I-5. Filtration I: The suspension of the
precipitated calcium sulphate and the solution of
polypeptide mixtures, peptides and amino acids are fed to a
filter where the calcium sulphate is completely separated
from the solution.
I-6. Heat treatment (first sterilisation step): The
alkaline solution of polypeptide mixtures, peptides and amino
acids (pH
³
11) is treated in a specific thermal
plant. This operation lasts about 6 hours: 2.5 hours for
heating to 140°C, 30 minutes at 140° (3.6 bars), and 2.5
hours for the cooling off.
I-7. Filtration II: By adding ammonium bicarbonate
Ca is separated from the solution.
I-8. Sterilisation: Heating to 132°C for 22 seconds
by direct steam injection.
I-9.
Concentration: The solution is concentrated to reach
a final product with up to 60% of dry matter.
I-
10. Drying: If required a drying may be added at an
air temperature of 220°C.
Scheme II
II-1 Homogenisation with alkaline treatment: The raw
material is ground, homogenised, heated (T 80 °C for 2 to 3
h) and treated with alkaline (pH >12).
II-2 Degreasing: The fat is separated from the mass
at the end of the homogenisation phase at pH 11.5 -12.0. It
is subsequently processed in a stripping plant, finally
stored and used for industrial applications.
II-3 Filtration: different techniques
applied.
II-4 Acid hydrolysis
9: The degreased and filtered raw material
is mixed with sulphuric acid (H
2SO
4) and heated to 70°C for 30 minutes at pH
1-2.
II-5 Calcium separation: The solution of hydrolysed
proteins (mixture of polypeptides, peptides and amino
acids) is treated with ammonium bicarbonate in order to
remove the calcium linked to the mixtures of polypeptides,
peptides and amino acids as calcium bicarbonate, which
precipitates. The calcium carbonate is separated from the
ammonium solution of the polypeptide mixtures, peptides and
amino acids.
II-6 Deodorification by oxygen gurgling.
II-7 Concentration: The solution is filtered to
reach a concentrated product with 58-60% of dry matter
(concentration at T° 53°C - 92°C).
II-8 Heat treatment (sterilisation): At pH
³
11 the alkaline solution is heated over 7h
to reach 140°C, kept at 140°C for 35 minutes (3.6bar), and
cooled down over 7h.
II-9 Drying: The product can be dried by spray
drying at air temperatures of 220°C.
3.32 Discussion of the potential of the different
production steps to contribute to a reduction of any
residual BSE infectivity.
The SSC is not aware of any completed
study specifically addressing the ability of the
manufacturing process of hydrolysed proteins to reduce or
eliminate BSE infectivity. The only ongoing study which was
brought to the attention of the SSC has not yet produced
any results. For the time being, and in view of the
apparent similarities, the following discussion is
therefore based on work carried out with regard to gelatine
production. It also extrapolates from other scientific
knowledge. This implies that a truly quantitative risk
assessment can not be carried out. As long as the
appropriate quantitative information is not available, the
risk assessment remains largely qualitative.
- The homogenisation, degreasing,
filtration and calcium-separation steps are unlikely to
reduce significantly a residual BSE infectivity because
they do not impact on the protein fraction.
- For the alkaline treatment it is
assumed that it has a significant capacity to reduce the
BSE-infectivity. This assumption is based on the only
available research results on this issue, which are
relating to the gelatine production process. Given the
higher temperature, at which this treatment is carried out
here, it can be assumed that at least a similar reduction
of any eventual BSE infectivity can be realised as for
gelatine. The fact that for the production of gelatine the
duration of the treatment is much longer is not regarded to
be relevant in this context because the (limited)
experimental results do not support the hypothesis that the
BSE-titre decreases with prolonged treatment
. It is therefore possible to assume that this step
will provide a significant reduction (See also the SSC
opinion on the Safety of Gelatine, adopted on 26-27 March
1998).
- There are no data upon which an
assessment of the inactivation effect of the acid
hydrolysis stage can be made. Therefore the SSC has not
currently assumed any reduction potential for this part of
the process.
- The heat treatment is considered to
have a significant reduction potential. The applied
conditions (140°C, 3.6bar, 30min) are more severe than
those which have shown a reduction potential of 10
3 (drying excluded) in the case of
rendering
17
.
The transformation process is not only
conducted at 140°C, 3.6Bar, 30 minutes, but also under
extremely alkaline conditions. According to the final
report of the
Validation Study of the Clearance of Scrapie from the
Manufacturing Process of Gelatine (Inveresk, 1998a,
1998b), the reduction factors indicate that the liming
treatments give a partial reduction of potential
infectivity. However, the level of reduction achieved
(reduction factor 2.33 log
10) is not increased as the length of the
incubation is extended. Moreover, combinations of
autoclaving and hydroxide have shown to be extremely
effective (even at 121°C) with rodent-passaged strains of
CJD and scrapie agent where the infectivity titres in the
brain-tissue were up to 10
10 ID
50/g (Prusiner et al, 1984; Taguchi et al, 1991;
Ernst & Race, 1993; Taylor et al, 1997). In addition,
unpublished data are showing inactivation after boiling for
a brief spell in alkali (D.Taylor, 1998, personal
communication).
As long as no other data are available
the SSC therefore assumes a reduction potential of at least
a similar order of magnitude for the heat treatment. It is
indeed not unlikely that the reduction capacity would be
even higher. Reasons are the more severe conditions and the
fact that the material is fluid and hence a better heating
kinetic can be assumed.
- The concentration and sterilisation
process, albeit also operating at high temperatures, are
not regarded to add to the infectivity reduction beyond the
level reached with the heat treatment.
Based on this discussion the SSC concludes that the
hydrolisation process, carried out as described above,
has a significant potential to reduce any possible BSE
infectivity in the initial fleshing. The severe heat
treatment and the alkaline treatment are regarded to be
the most relevant elements.
In view of the low titre of the input material, which
normally can be expected, the SSC regards it highly
likely that the final product, the hydrolysed proteins,
are BSE free. However, no experiments have been made so
far for the hydrolysis process as such
18
and all estimations have to be
regarded as preliminary until appropriate studies have
been carried out. It is also not certain that the
infectivity reduction achieved at the different steps is
fully additive. Further it is also not known if the
resistance of any surviving infectivity would be
enhanced, the so-called tailing effect has not yet been
excluded to apply to the BSE-agent.
An experimental verification of the
capacity of the overall process to reduce or eliminate
BSE infectivity is needed.
3.4 The role of the final use of the
product as regard to the transfer of BSE to animal or
man.
3.41 Use in animal feed
Current use: Hydrolysed proteins are fed
to animals, including bovines. For example: for dairy cows,
the daily intake rate may reach about 100g dry mass of
hydrolysed proteins.
Importance of such an use:
- Allowable daily intake, oral: The oral
minimum infective dose of BSE-contaminated material is not
known, even for bovines. On the basis of currently
available information the bovine threshold for a single
oral dose of BSE infective material can be assumed to be
below 1g of infected brain. Current estimates assume 0.1g
to be sufficient to trigger infectivity in bovines (UK,
MAFF-CVL, personal communication). There is evidence that
the incubation time increases with smaller doses and hence
this lower threshold level could not yet be verified by
experiments. For other species no estimation of the
threshold dose is available. However, it can be assumed
that small ruminants may be equally sensitive.
- No information is available as to the
impact of repeated small doses on cattle. The only
experiment (Diringer
et al, 1998) was carried out with scrapie in
Hamster. It points, however, to a certain risk that small
doses, given at short intervals, could accumulate to some
extend.
- As long as the threshold value is not
known it must be assumed that also a small dose would
finally lead to a BSE case if a sufficiently large number
of animals would be exposed to it.
3.42 Use as fertiliser
Hydrolysed proteins are used as
fertiliser, mainly in horticulture, for example included in
culture media for propagation of seedlings, cuttings,
etc.
The working group that its use as fertiliser can be
regarded as safe if the hydrolysed protein is regarded to
be safe. The conditions for reaching this degree of
safety are defined in this report. Whenever this degree
of safety is not guaranteed, hydrolysed proteins should
not be used as fertiliser because a residual
BSE-infectivity could not be fully excluded. Besides the
risk of accidental exposure of man or ruminants to the
agent, the unclear fate of the agent in the environment
requires this precautionary approach.
4. References
- Assalzoo, 1998a. Technique report of 28 May 1998:
"Documentazione tecnica riguardante la trasformazione del
carniccio in idrolizzato proteico per l'alimentazione del
bestiame: procedimento di lavorazione per l'ottenimento di
idrolizzati proteici di origine animale delle due aziende
associate."
-
Assalzoo, 1998b. Technique report of 12 June
1998:"Documentazione tecnica riguardante la trasformazione
del carniccio in idrolizzato proteico per l'alimentazione
del bestiame: composizione analitica delle tipologie
fondamentali di idrolizzati prodotti dalle due aziende
associate."
-
Casolari, A., 1998. Heat resistance of prions and
food processing. Food Microbiology, 1998, 59-63
-
Dickinson, A.G., Taylor, D.M., 1978. Resistance of
scrapie agent to decontamination. New England Journal of
Medicine,
299
, 1413-1414.
- Diringer, H., Roehmez, J., Beekes, M., 1998.
Effect of repeated oral infection of hamsters with scrapie.
J.Gen.Virol.,
79
, 609-612.
-
Dormont, D., 1997. Sécurité du phosphate bicalcique.
Projet d'avis destiné au Comité Scientifique
Multidisciplinaire de l'Union Européenne.
-
E.C. (European Commission), 1994. Commission
Decision 94/381/EC, concerning certain protection measures
with regard to BSE and the feeding of mammalian derived
protein, OJ L 172, 7.7.94, p.23
- EC, (European Commission), 1994. Scientific
Veterinary Committee, Report from the Scientific Veterinary
Committee on the risk from BSE of some products derived
from ruminants. Adopted on 12 December 1994
- E.C. (European Commission), 1995. Commission
Decision 95/60/EC, amendment to Commission Decision
94/381/EC; OJ L 55, 11.3.95, p.43
-
E.C. (European Commission), 1996a. Scientific
opinion adopted on 9.04.96 by the Scientific Veterinary
Committee on Specified risk materials and on the safety of
meat and bone meal and of tallow.
- E.C. (European Commission), 1996b. The Scientific
Committee Food. Opinion of 15 April 1996. Products derived
from bovine tissues, especially gelatine, tallow and
dicalcium phosphate in relation with Bovine Spongiform
Encephalopathy.
-
E.C. (European Commission), 1996c. Commission
Decision of 11 June 1996, 96/362/EC. Modification of
Decision 96/239/CE relative to the emergency measure for
the protection against Bovine Spongiform Encephalopathy. GU
n. L 139 of 12.06.96 pg.17.
- E.C. (European Commission), 1997a. The Scientific
Steering Committee (Multi-Disciplinary Scientific
Committee). The situation of gelatine and related products.
Opinion of 3 April 1997. MDSC/SG/97/042.
- E.C. (European Commission), 1997b. The Scientific
Steering Committee. Listing of Specified Risk Materials: a
scheme for assessing relative risks to man. Opinion adopted
on 9 December 1997.
- E.C. (European Commission), 1998a. The Scientific
Steering Committee. Opinion of SSC 22-23 January 1998,
defining the BSE risk for specified geographical
areas.
- E.C. (European Commission), 1998b. The Scientific
Steering Committee. Opinion on the contents of a "complete
dossier of the epidemiological status of respect to TSEs."
Adopted by the SSC at its plenary meeting of 19-20 February
1998.
- E.C. (European Commission), 1998c. The Scientific
Steering Committee. The safety of gelatine. Opinion adopted
on 26-27 March 1998.
- E.C. (European Commission), 1998d."Report and
opinion on the safety of dicalcium phosphate precipitated
from ruminants bones and used as an animal feed additive"-
Adopted at the Scientific Steering Committee at its plenary
meeting of 25-26 June 1998.
- E.C. (European Commission), 1998d."Report and
opinion on the safety of Mammalian Meat and Bone Meal
(MMBM) for the use as an animal feed for non-ruminant
food-producing animals"- Presented to the Scientific
Steering Committee at its plenary meeting of 24-25
September 1998.
- Ersnt, D.R. & Race, R.E., 1993. Journal of
Virological Methods,
41
, p. 193.
- G.M.E (Gelatin Manufactures of Europe), 1997.
Study of the reduction of TSE infectivity by the production
processes of limed bone gelatine and acid bone gelatine.
Research protocol. Attached to the letter of 18.11.98 of
G.M.E. to the Director general of DGXXIV.
- G.M.E (Gelatin Manufactures of Europe), 1998a.
Letter of 8 January 1998 to the secretariat of the
Scientific Steering Committee, containing clarifications
and technical annexes on gelatine and dicalcium phosphate
production data, chemical composition, raw materials used,
production processes, etc. Complemented with a letter of
19.01.98 providing clarifications on the letter of
8.01.98.
-
G.M.E (Gelatin Manufactures of Europe), 1998b.
Complement to GME (1998a), with additional information on
the Gelatine European Market and on the Study on the effect
of the gelatine manufacturing process on the TSE
infectivity.
-
G.M.E (Gelatin Manufactures of Europe), 1998c.
Letter of 16 March 1998 to the secretariat of the
Scientific Steering Committee, containing comments to the
Preliminary Opinion on the Safety of Gelatine adopted by
the SSC on 19-20 February 1998.
- Groschup, Martin H., Frank Weiland, Otto Christian
Straub and Eberhard Pfaff, 1996. Detection of Scrapie
Agent in the Peripheral Nervous System of a Diseased Sheep.
Neurobiology of Disease,
3
, 191-195.
-
Inveresk Research International, 1995. Validation of
the clearance of Scrapie from the manufacturing process of
gelatine. Interim Data Summary of the Inveresk Project
N°851180 sponsored by GME (Gelatin Manufactures Europe).
Report N°10288 by M. Pubkis. Tratent (Scotland), 31
pp.
-
Inveresk Research International, 1998a. Validation
of the clearance of Scrapie from the manufacturing process
of gelatine. Final Report N°14682 of the Inveresk Project
N°855028 sponsored by GME Gelatin Manufactures Europe.
Tratent (Scotland), 41 pp.
-
Inveresk Research International, 1998b. Validation
of the clearance of Scrapie from the manufacturing process
of gelatine: additional stage. Final report N° 14683 of the
Inveresk Project N°855028 sponsored by GME Gelatin
Manufactures Europe. Tratent (Scotland), 28 pp.
-
Kimberlin, R.H., Walker, C.A., Millson, G.C., Taylor,
D.M., Roberston, P.A., Tomlinson, A.H., Dickinson, A.G.,
1983. Disinfection studies with two strains of
mouse-passages scrapie agent. J.Neurol.Sci.,
59
, 355-369.
-
Mantze, U., Schalf, G., Poethke, R., Felgenhauer, K.,
Mäder, M., 1996. On the Removal of nervous Proteins
from Material Used for Gelatin Manufacturing During
Processing. Pharm.Ind.,
58
, 837-841.
Prusiner, S.B., et al, 1994. Methods in Virology,
Vol.III, p.293
-
OIE (Office International des Epizooties), 1997.
Bovine Spongiform Encephalopathy (BSE). Chapter 3.2.13 of
the OIE International Zoo-Sanitary Code on BSE.
-
OIE (Office International des Epizooties), 1998.
66th Annual General Meeting Session of the International
Committee of OIE. New version of the OIE International
Animal Health Code on BSE of 29 May 1998.
-
Pascal, G., 1998. Note of 23 May 1998 on a draft
report on The Safety of Amino acids and peptides-
Hydrolysed proteins".
-
Piva G., 1998. TSE/BSE clearance factors of
production processes of gelatine and dicalcium phosphate
precipitated from bone-protein hydrolysed. Technical notes
provided to the Scientific Steering Committee.
-
République Française, 1996. Comité Interministériel
sur les Encéphalopathies Subaiguës Spongiformes
Transmissibles. Réponses aux questions du Directeur Général
de la Santé, du Directeur Général de l'Alimentation et du
Directeur Général de la Consommation, de la Concurrence et
de la Dépression des Fraudes, addressées au Comité en
juillet 1996.
-
Rohwer, R.G., 1991. The Scrapie Agent: "A virus by
any other name- Current topics in microbiology and
immunology", Springer- Verlag Heidelberg, Volume
172.
- Schrieber, R., Seybold, H., 1993. Gelatine
production, the six steps to maximum safety. In: Brown, F.,
(Editor), 1993. Transmissible Spongiform Encephalopathies -
Impact on Animal and Human health. Dev.Biol.Stand., Basel,
Karger,
80
, 195-198.
- Schreuder, B.E.C., Geertsma, R.E., van Keulen, L.J.M.,
van Asten, J.A.A.M., Enthoven, P., Oberthür, R.C., de
Koeijer, A.A., Osterhaus, A.D.M.E., 1998. Studies on
the efficacy of hyperbaric rendering procedures in
inactivating bovine spongiform encephalopathy (BSE) and
scrapie agents. The Veterinary Record,
142
, 474-480.
- Stryer, 1981. Biochemistry. Editions Freeman. San
Francisco (US).
-
Taguchi, F. et al, 1981. Archives in Virology,
199
, p.297.
-
Taylor, D.M., and Fernie, K.(1996). Exposure to
autoclaving or sodium hydroxide extends the dose-response
curve of the 263K strain of scrapie agent in hamsters.
Journal of General Virology,
77
, 811-813.
-
Taylor, D.M., Fraser, H., McConell, I., Brown, D.A.,
Brown, K.L., Lamza, K.A., Smith, G.R.A., 1994.
Decontamination studies with the agents of Bovine
Spongiform Encephalopathy and Scrapie. Archives of
Virology,
139
, 313-326.
- Taylor D.M. et al., 1997. Veterinary
Microbiology,
58,
p.87
-
Taylor, D.M. 1998. Practical problems in
inactivating BSE-like agents. Proceedings of the 5
th International Feed Production Conference,
Piacenza, June 15-18, 1998. In press.
- U.S.-F.D.A. (Food and Drug Administration, Department
of Health and Human Services, United States of America),
1997. Verbatim (Proceedings) of the meeting of 23 April
1997 of the Transmissible Spongiform Encephalopathies
Advisory Committee. Washington, D.C. (USA), 232 pp.
- U.S.-F.D.A. (Food and Drug Administration, Department
of Health and Human Services, United States of America),
1997. Bovine Spongiform Encephalopathy (BSE) in
products for human use; Guidance for Industry on the
Sourcing and Processing of gelatine to Reduce Potential
Risk; Availability. Docket N°97D-0411. Washigton, D.C.
(USA), 4+15 pp.
- Wells, G.A.H., Hawkins, S.A.C., Green, R.B., Austin,
A.R., Dexter, I., Spencer, Y.I., Chaplin, M.J., Stack,
M.J., Dawson, M., 1998. Preliminary observations on the
pathogenesis of experimental bovine spongiform
encephalopathy (BSE): an update. Veterinary Record, Vol.
142: pp 103-106.
-
WHO, 1997, Consultation on Medicinal and other
Products in relation to Human and Animal Transmissible
Spongiform Encephalopathies, Switzerland, 24-26 March,
1997
5. Acknowledgements
The present report of the working group
is substantially based on the work of chaired by
Prof.Dr.M.Vanbelle. Other members of the working group
were: Prof.Dr.R.Böhm, Prof.Dr. Prof.Dr.D.Dormont,
Prof.Dr.DVM. Esko Nurmi, Prof.Dr. A.-L.Parodi Prof.Dr.
G.Piva, Dr. M.Riedinger, Dr B.Schreuder, Prof.Dr. P.Sequi,
Prof.Soren Alexandersen, Dr.D.Taylor, Dr. H.A.P. Urlings,
Prof.Dr. M.Wierup, Prof.Dr. P.Willeberg.
Annex 1
:
Extract from the SSC minutes of 25-26 May 2000, on the
basis of the TSE/BSE
ad hoc Group's discussions at its meeting of 11 May
2000
1. At its meeting of 22-23 October 1998,
the Scientific Steering Committee Adopted a Report and
Scientific Opinion on the safety of hydrolysed proteins
produced from bovine hides. This opinion recommends a
number of conditions with respect to sourcing and
transformation process of the raw material. Regarding the
transformation process, the opinion considers that "
controlling the molecular weight would provide a good
verification of the appropriateness of an applied
transformation process. A value of a maximum molecular
weight of the hydrolysed proteins below 10.000 Daltons
could be used as an indicator."
2. At its meeting of 22-23 April 1999,
the SSC decided that its Opinion of 22-23 October 1998 on
the Safety of Hydrolysed Proteins would need to be updated
in view of the following considerations:
"On the basis of the reasoning given in
annex 2, the TSE/BSE
ad hoc Group concluded at its meeting of 15 April
1999, that declaring hydrolysed proteins safe if the
resulting peptides are less than 10.000 Daltons, could lead
to a false sense of security. The ad hoc Group further
concluded that the sourcing and (severe) processing
conditions recommended in its opinion of 22-23 October
1998, together with the fact that bovine hides as such are
not a specified risk material, are sufficient conditions
for the final product to be safe. It further reiterated
that any approval of other production processes should be
done on a case by case basis and on the basis of the
results of a report with research results with respect to
the inactivation of TSE/BSE infectivity by the
process."
3. The question can further be raised
whether the figure of 10.000 Daltons is to be considered as
an absolute threshold, i.e., that the product is unsafe if
any molecules with a MW above 10.000D are found, or as a
qualitative indicator of an average MW reflecting that
after processing, the size of the molecules has a
statistical spread and that a certain fraction of the
molecules may have a MW above 10.000D. This would imply
that the product after the hydrolysation process described
in the opinion, is safe also if a small fraction [say 1-5%,
to be defined on the basis of laboratory analyses] of
hydrolysed proteins has a MW above 10.000.
The second option can be accepted only
if it would not jeopardise the safety of the final product.
Taking into account the following elements:
- the sourcing and (severe) processing
conditions recommended in its opinion of 22-23 October
1998, together with the fact that bovine hides as such are
not a specified risk material, are sufficient conditions
for the final product to be safe.
- As can be derived from Annex 2, the
minimum size of the fraction of a PrP
Sc prion that could be infectious is not known.
It may also be below 10.000.
- No standardised and generally
acknowledged methods for the determination of the MW of
hydrolysed peptides exist,
having regard to considerations provided
by the TSE/BSE ad-hoc group at its meeting of 11 May 2000
and which are detailed in the annexes 1, 2 and 3, it may be
concluded that a molecular weight of <10.000D cannot be
seen as an absolute guarantee for safety, per se. The
criterion is indicative, and not exclusive for the quality
of the hydrolysing process and of the safety regarding
possible residual TSE infectivity of the final product. It
seems theoretically possible that the infectious fraction
(segment, part) of the BSE-agent could be smaller. However,
a product with most of the molecules having a MW of <
10.000D has most likely been produced by means of
production processes which, together with appropriate
sourcing and respecting the other safety conditions given
in the above cited SSC-opinion, guarantee a safe product. A
limited range of molecular weights above the target value
of less than 10.000D is therefore unlikely to affect the
safety of the final product, provided, of course, all the
other criteria of the opinion are complied with. Thus, a
molecular weight below 10.000D may be used as an indicator
but not as a safety guarantee per se.
Annex 2: Short report to the SSCon the basis of a
Working Group report drafted by Dr.D.M.Taylor.
Subject: Hydrolysed proteins: are they more safe
if their molecular weight is less than 10kD?
It has been argued that these products
might be considered to be safe if the hydrolysed proteins
have a MW of <10 kD. The basis for such a suggestion
would be the knowledge that PrP
sc has a MW of 27-30kD.
The TSE/BSE ad hoc Group is of the
opinion that the use of such a criterion could lead to a
false sense of security because it is not known whether
protein sub-components or peptides of low MW derived from
PrP
Sc can trigger the conversion of PrP
C to PrP
Sc. However, one needs to bear in mind that the
27-30 kD PrP
Sc is itself a sub-component. It is the
resistant 'core' that remains after proteolytic digestion
of the full-length PrP
Sc protein that has a MW of 33-35kDa. Therefore,
there is existing formal proof that a somewhat truncated
form of PrP
Sc can convert PrP
C into PrP
Sc. It is known that more severely truncated
forms of PrP
C can be converted to PrP
Sc. For example, a PrP
C peptide consisting of only 21 residues had
properties akin to PrP
Sc.
6 It was neurotoxic, and had a tendency to form
amyloid fibrils analogous to the scrapie-associated fibrils
(SAF) found in brain extracts from TSE-infected
individuals. It must be assumed that this truncated form of
PrP
Sc might convert non-truncated PrP
C to PrP
Sc. Also, a form of PrP
C containing only 106 residues (MW approximately
10 kDa) was converted to PrP
Sc
in vitro.
7 In addition, when this truncated PrP was
expressed in transgenic mice that were deficient for
wild-type PrP, these mice developed scrapie when challenged
with the RML strain of mouse-passaged scrapie agent,
demonstrating the convertibility of this 106 residue PrP
C to PrP
Sc.
8 More importantly, when brain-tissue from the
scrapie-infected PrP106 mice was passaged into mice of the
same genotype, they developed scrapie.
8 These data confirm that PrP
C peptides with a MW of approximately 10 kDa can
not only be converted to PrP
Sc, but that they can also convert PrP
C to PrP
Sc. The above data tend to confirm the opinion
that declaring hydrolysed proteins safe if the resulting
peptides are <10 kDa could lead to a false sense of
security.
The TSE/BSE
ad hoc Group considers that only low levels of BSE
infectivity could be present in the raw materials. The two
typical manufacturing processes described in the SSC
opinion of 22-23 October 1998 are likely to
reduce very significantly
even considerably higher levels of BSE infectivity
than could ever be present under worst-case conditions.
This is because of the combinations of heat (especially
steam under pressure) and alkali that are used. A variety
of data are available that show the effectiveness of heat
combined with alkali on BSE and scrapie agents.
1-5
References
1.
Ernst, D.R. and Race, R.E. 1993. Comparative
analysis of scrapie agent inactivation. J. Virol.
Methods,41; 193-202.
2.
Prusiner, S.B., McKinley, M.P., Bolton, D.C., Bowman,
K.A., Groth, D.F., Cochran, S.P., Hennessey, E.M.,
Braunfeld, M.B., Baringer, J.R. and Chatigny, M.A.
1984. Prions: methods for assay, purification, and
characterisation. In: K. Maramorosch and H. Koprowski
(Editors), Methods in Virology, 8. Academic Press, New
York, pp 293-345.
3.
Taguchi, F., Tamai, Y., Uchida, K., Kitajima, R.,
Kojima, H., Kawaguchi, T., Ohtani, Y. and Miura, S.
1991. Proposal for a procedure for complete
inactivation of the Creutzfeldt-Jakob disease agent. Arch
Virol, 119; 297-301.
4.
Taylor, D.M, Fernie, K. and McConnell, I., 1997.
Inactivation of the 22A strain of scrapie agent by
autoclaving in sodium hydroxide. Vet Microbiol 58.
87-91.
5.
Taylor, D.M., Fernie, K. & Steele, P.J., 1999.
Boiling in sodium hydroxide inactivates mouse-passaged BSE
agent. Abstracts of a Meeting of the Association of
Veterinary Teachers and Research Workers. p 22.
Scarborough; 29 March-1 April 1999.
6.
Forlini, G., Angeretti, N., Chiesa, R., Monzani, E.,
Salmona, M., Bugiani, O. & Tagliavini, F., 1993.
Neurotoxicity of a prion protein fragment.
Nature
362, 543-546.
7.
Muramoto, T., Scott, M., Cohen, F.E. & Prusiner,
S.B., 1996 Recombinant scrapie-like protein of 106
amino acids is soluble. Proc Nat Acad Sci 93,
15457-16462.
8.
Supattapone,S., Bosque, P., Muramoto, T., Wille, H.,
Aagaard, C., Peretz, D., Nguyen,H.O., Heinrich, C.,
Torchia, C., Safar, J., Cohen, F.E., DeArmond, S.J.
Prusiner, S.B. & Scott, M., 1999. Prion protein of
106 residues creates an artificial transmision barrier for
prion replication in transgenic mice.
Cell
96, 869-878.
Annex 3:
Notes on the size of non-conventional transmissible
agents causative of TSE
Prof.Dr.D.Dormont, submitted to the TSE/BSE ad hoc
Group at its meeting of 9 September 1999
Preliminary comments:
1) The linear relationship between the
quantity of PrP partly resistant to proteinase K and
infective titre has been verified in experimental models
using a stabilised strain of NCTA. It is more difficult to
demonstrate this relationship in the case of primary
transmission.
2) To date trials involving injecting
animals with the fully purified pathological prion protein
(PrP-res) (extraction of the electrophoresis gel followed
by renaturation) have never led to transmission of the
disease; the same goes for recombinant PrP protein and for
peptides that have neurotoxic properties
in vitro (PrP 106-126).
3) Bearing in mind the uncertainties
that still persist as to the nature of NCTAs, it is
impossible to measure the exact size of the agent. Only an
approximation of the size of the infective unit is possible
(result of inoculation of the test animal).
4) The size of the PrP-c molecule
measured in RMN is 38 Angströms for the corpuscular part
and 300 Angströms for the flexible N-terminal part; no data
of this kind are available for pathological PrP (10,
11).
Methods used:
There are two methods:
1) estimation of the size on the basis
of gamma ray inactivation data;
2) estimation of the size on the basis
of data obtained from zonal centrifugation, ultrafiltration
and exclusion chromatography.
Main results:
- The radiobiology data indicate that
the NCTAs are very small, between 64000 and 150000Da (1, 3,
4); however, these data do not make allowances for
aggregation, a property which has been demonstrated for
NCTAs by many teams. Besides, most of these data were
obtained by irradiating brain homogenates, where the
profusion of complex lipids may bias the results and lead
to an overestimate of the radioresistance of the infective
agent.
- The zonal centrification data indicate
that the agent's sedimentation coefficient lies between 40S
and 500S (7-9) (compare with parvoviruses, whose
sedimentation coefficient is 100/110S (12)).
- The ultrafiltration trials with
variable porosity filters followed by titration of the
filtrate point to a size of 15 to 40nm. By way of example,
an ultrafiltration with an exclusion threshold of 100 kD
reduces the infective titre of a scrapies strain by 2.2
logs, whereas a membrane with a threshold of 30 kD reduces
it by 4.9 logs and a membrane with a threshold of 10 kD
reduces it by more than 6.5 logs (no infectivity
detectable) (5) (6) (2).
The exclusion chromatography data show
that the size of the agent lies between 30 and 50nm.
However, these measurements should be
interpreted bearing in mind that the NCTAs can very readily
aggregate; hence these methods may overestimate the
size.
- Certain nanofiltration trials have
been carried out; a 25 nm filtration can reduce infectivity
by approximately 2 logs; nanofiltration at 35 nm is
relatively ineffective. By contrast, nanofiltration at 15
nm seems to be capable of eliminating all infectivity, even
when the agent has first been treated with detergents to
compensate for aggregation as much as possible (results
obtained by a Japanese team).
To sum up: two factors must be considered in the
scientific discussion: 1) the agent is small, of the order
of 15 to 40 nm; 2) pursuant to the prion hypothesis,
according to S.B.Prusiner, the infective unit contains 10
5 molecules of pathological proteinase
K-resistant PrP.
Références bibliographiques :
----------------------------------------
1
See also the opinion of the SSC on the
safety of MMBM for non-ruminant food-producing animals,
September 1998
2
Healthy animals are defined as animals
which have undergone an ante mortem inspection by an official
veterinarian where it was determined that the animals were
not suffering from a disease which is communicable to man and
animals and that they do not show symptoms or are in a
general condition such as to indicate that such disease may
occur and they show no symptoms of disease or of a disorder
of their general conditions which is likely to make their
meat unfit for human consumption.
3
See also the opinion of the SSC on the
safety of MMBM for non-ruminant food-producing animals, 26-27
March 1998
4
See the report of the Working Group
attached to this opinion.
5
Opinion of the SSC on the date based
export scheme (9/12/97 and 20/2/98) and of the Scientific
Veterinary Committee on the revised UK certified herds scheme
(17/9/97)
6
An opinion of the SSC on the criteria for
closed herds guaranteeing that animals from these herds are
BSE-free is forthcoming.
7
Hazard Analysis and Critical Control
Points
8
OJ L 172, 7.7.94, p.23
9
OJ L 55, 11.3.95, p.43
10
Report from the Scientific Veterinary
Committee on the risk from BSE of some products derived from
ruminants. Adopted on 12 December 1994
11
See reference list.
12
Not in all cases
13
Consultation on Medicinal and other
Products in relation to Human and Animal Transmissible
Spongiform Encephalopathies, Switzerland, 24-26 March,
1997
14
SSC "Safety of bi-calcium phosphate".
Preliminary opinion adopted on 15/5/98
15
SSC opinion on safety of Gelatine, March
98
16
Not in all cases applied.
17
See also the opinion of the SSC on the
safety of MMBM for non-ruminant food-producing animals,
September 1998
18
A study of the reduction potential is
currently underway but no results are yet
available.
[
©]
- [
HEALTH] - [
SCIENTIFIC COMMITTEES] - [
SCIENTIFIC STEERING COMMITTEE] -
[
OUTCOME OF DISCUSSIONS]
|